Long-term efficacy of insulin glargine therapy with an educational programme in type 1 diabetes patients in clinical practice

References

• Cryer P. Hypoglycemia is the limiting factor in the management of diabetes. Diabetes Metab Res Rev 1999;15:42–6
   PubMed Web of Science ®Google Scholar
• DCCT. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993;329:977–86
   Google Scholar
• Lepore M, Pampanelli S, Fanelli C, et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 2000;49:2142–8
   PubMed Web of Science ®Google Scholar
• Yki-Jarvinen H, Kauppila M, Kujansuu E, et al. Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1992;327:1426–33
   Google Scholar
• Pieber T, Eugene-Jolchine I, Derobert E. Efficacy and safety of HOE901 versus NPH insulin in patients with type 1 diabetes. Diabetes Care 2000;23:157–62
   PubMed Web of Science ®Google Scholar
• Raskin P, Klaff L, Bergenstal R, et al. A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes. Diabetes Care 2000;23:1666–71
   PubMed Web of Science ®Google Scholar
• Heinemann L, Linkeschowa R, Rave K, et al. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care 2000;23:644–9
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Schwartz SL, Clark CMJ, et al. Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care 2001;24:631–6
   PubMed Web of Science ®Google Scholar
• Yki-Jarvinen H, Dressler A, Ziemen M. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. Diabetes Care 2000;23: 1130–6
   Google Scholar
• Ratner RE, Hirsch IB, Neifing JL, et al Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. Diabetes Care 2000;23:639–43
   PubMed Web of Science ®Google Scholar
• Schreiber SA, Russmann A. The effects of insulin glargine treatment and an educational programme on glycaemic control in type 2 diabetes patients in clinical practice. Curr Med Res Opin 2006;22:335–41
   PubMed Web of Science ®Google Scholar
• Schreiber SA, Russmann A. Insulin glargine and educational intervention in patients with type 2 diabetes in clinical practice: long-term improvement in glycaemic control without weight gain. Exp Clin Endocrinol Diabetes 2006;114:41–2
   PubMed Web of Science ®Google Scholar
• Mollema ED, Snoek FJ, Ader HJ, et al. Insulin-treated diabetes patients with fear of self-injecting or fear of self-testing: psychological comorbidity and general well-being. J Psychosom Res 2001;51:665–72
   PubMed Web of Science ®Google Scholar
• Berlin I, Bisserbe JC, Eiber R, et al. Phobic symptoms, particularly the fear of blood and injury, are associated with poor glycemic control in type I diabetic adults. Diabetes Care 1997;20:176–8
   PubMed Web of Science ®Google Scholar
• Cryer PE. Hypoglycaemia: the limiting factor in the glycaemic management of type I and type II diabetes. Diabetologia 2002;45:937–48
   PubMed Web of Science ®Google Scholar
• Rubin R, Peyrot M, Saudek CD. Effect of diabetes education on self-care, metabolic control, and emotional well-being. Diabetes Care 1989;12:673–9
   PubMed Web of Science ®Google Scholar
• Langewitz W, Wossmer B, Iseli J, Berger W. Psychological and metabolic improvement after an outpatient teaching program for functional intensified insulin therapy (FIT). Diabetes Res Clin Pract 1997;37:157–64
   PubMed Web of Science ®Google Scholar
• Schiel R, Ulbrich S, Muller U. Quality of diabetes care, diabetes knowledge and risk of severe hypoglycaemia one and four years after participation in a 5-day structured treatment and teaching programme for intensified insulin therapy. Diabetes Metab 1998;24: 509–14
   Google Scholar
• Graziani C, Rosenthal M, Diamond J. Diabetes education program use and patient-perceived barriers to attendance. Fam Med 1999;31:358–63
   Google Scholar
• Tankova T, Dakovska G, Koev D. Education of diabetic patients - a one year experience. Patient Educ Couns 2001;43: 139–45
   PubMed Web of Science ®Google Scholar
• Lemonzy-Cadroy S, Crognier S, Gourdy P et al. Intensified treatment of type 1 diabetes: prospective evaluation at one year of a therapeutic patient education programme. Diabetes Metab 2002;28(4 pt 1):287–94
   Google Scholar
• Sinha A FC, Tsalamandris C, Panagiotopoulos S, et al. Effects of insulin on body composition in patients with insulin-dependent and non-insulin-dependent diabetes. Diabet Med 1996;13:40–6
   PubMed Web of Science ®Google Scholar
• DCCT. Influence of intensive diabetes treatment on body weight and composition of adults with type 1 diabetes in the Diabetes Control and Complications Trial. Diabetes Care 2001;24:1711–21
   PubMed Web of Science ®Google Scholar
• Purnell JQ, Hokanson JE, Marcovina SM, et al. Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: results from the DCCT. Diabetes Control and Complications Trial. JAMA 1998;280:140–6
   Google Scholar
• Grimaldi A, Vialettes B, Blayo A, et al. Comparison of dinner with bedtime administration of insulin glargine in type 1 diabetic patients treated with basal-bolus regimen. Diabetes Metab 2007;33:121–8
   PubMed Web of Science ®Google Scholar
• Chatterjee S, Jarvis-Kay J, Rengarajan T, et al. Glargine versus NPH insulin: Efficacy in comparison with insulin aspart in a basal bolus regimen in type 1 diabetes – the glargine and aspart study (GLASS) a randomised cross-over study. Diabetes Res Clin Pract 2007;77:215–22
   PubMed Web of Science ®Google Scholar
• Home PD, Rosskamp R, Forjanic-Klapproth J, Dressler A. A randomized multicentre trial of insulin glargine compared with NPH insulin in people with type 1 diabetes. Diabetes Metab Res Rev 2005;21: 545–53
   Google Scholar
• Gomis R, Storms F, Conget I, Sinnassamy P, Davies M. Improving metabolic control in sub-optimally controlled subjects with type 1 diabetes: Comparison of two treatment algorithms using insulin glargine. Diabetes Res Clin Pract 2007;77: 84–91
   Google Scholar